Evolución de la innovación educativa en la Universidad Complutense: proyecto UNICOMEX

La evolución de la educación universitaria en España ha experimentado una enorme evolución en los últimos veinte años. Desde la enseñanza centrada en la clase magistral, con el consiguiente protagonismo del profesor, a lo que sucede actualmente, con el estudiante como eje principal, media todo un cambio en el planteamiento de nuestro sistema educativo universitario. La implantación del Espacio Europeo de Educación Superior (EEES) ha sido uno de los objetivos perseguidos por la Universidad Complutense de Madrid (UCM) en la última década. Con este fin existieron, hasta hace poco, las conocidas como Asignaturas Piloto (AP) e igualmente se convocan periódicamente, desde hace años, los Proyectos de Innovación Educativa (P.I.E.). Ambas herramientas han procurado facilitar dicha adaptación, así como promover un concepto transversal en la transmisión del conocimiento. Nuestro grupo de trabajo puede ser un ejemplo de lo que la UCM ha querido conseguir con ambas cosas. La asignatura ha participado en todas las convocatorias de AP, pasando por una evolución clara desde la clase magistral a los pequeños grupos de trabajo. Ha sido, además, el instrumento útil para ir desarrollando distintos P.I.E., hasta un total de nueve, tras formar un equipo interdisciplinar constituido por profesores universitarios y profesionales de diversos ámbitos. El último de estos PIE, concedido en el curso académico 2011-2012, consiste en la creación de un espacio virtual de referencia para el estudio de los animales exóticos, partiendo de los resultados obtenidos en proyectos anteriores. UNICOMEX (Universidad-Complutense-Exóticos) nace con el objetivo de poner al alcance de cualquiera una serie de recursos virtuales ordenados que faciliten el conocimiento biológico, anatómico y clínico de los animales exóticos, entendiendo como tales aquellos que, siendo de interés veterinario, no se consideran domésticos. La totalidad de su contenido está en español e inglés, con el fin de hacer de ella una herramienta virtual útil y abierta a la comunidad científica y didáctica internacional

The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry

Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in Europe. Data from real-world registries are necessary, as clinical trials do not represent the full spectrum of VTE patients seen in clinical practice. We aimed to document the epidemiology, management and outcomes of VTE using data from a large, observational database. PREFER in VTE was an international, non-interventional disease registry conducted between January 2013 and July 2015 in primary and secondary care across seven European countries. Consecutive patients with acute VTE were documented and followed up over 12 months. PREFER in VTE included 3,455 patients with a mean age of 60.8 ± 17.0 years. Overall, 53.0 % were male. The majority of patients were assessed in the hospital setting as inpatients or outpatients (78.5 %). The diagnosis was deep-vein thrombosis (DVT) in 59.5 % and pulmonary embolism (PE) in 40.5 %. The most common comorbidities were the various types of cardiovascular disease (excluding hypertension; 45.5 %), hypertension (42.3 %) and dyslipidaemia (21.1 %). Following the index VTE, a large proportion of patients received initial therapy with heparin (73.2 %), almost half received a vitamin K antagonist (48.7 %) and nearly a quarter received a DOAC (24.5 %). Almost a quarter of all presentations were for recurrent VTE, with >80 % of previous episodes having occurred more than 12 months prior to baseline. In conclusion, PREFER in VTE has provided contemporary insights into VTE patients and their real-world management, including their baseline characteristics, risk factors, disease history, symptoms and signs, initial therapy and outcomes

Synthesis and properties of multifunctional tetragonal Eu:GdPO4 nanocubes for optical and magnetic resonance imaging applications

A simple and fast (7 min) procedure for synthesis of gadolinium phosphate nanocubes (edge = 75 nm) based on the microwave-assisted heating at 120 C of gadolinium acetylacetonate and phosphoric acid solutions in buthylene glycol is reported. These nanocubes were highly crystalline and crystallized into a tetragonal structure, which has not been ever reported for pure gadolinium phosphate. Determination of such crystal structure has been carried out here for the first time in the literature by means of powder X-ray diffraction. The developed synthesis procedure was also successful for preparation of multifunctional europium(III)-doped the gadolinium phosphate nanocubes, which were nontoxic for cells and exhibited strong red luminescence under UV illumination and high transverse relaxivity (r2) values. These properties confer them potential applications as biolabels for in vitro optical imaging and as negative contrast agent for magnetic resonance imaging. © 2012 American Chemical Society.Peer Reviewe

The management of patients with venous thromboembolism in Italy: insights from the PREFER in VTE registry

Venous thromboembolism (VTE) is the third most common cardiovascular disease. Real-life data on the clinical presentation, risk factors, diagnosis, and treatment of VTE in Italy and Europe are required to optimize the management of this disease. The PREFER in VTE registry, a prospective non-interventional real-life study, was designed to assess clinical characteristics and management of patients with VTE, use of health care resources, and on-treatment patient quality of life. Eligible consecutive patients with objectively diagnosed VTE were enrolled in the registry and followed up for 12 months. Between January and December 2013, 816 Italian and 1027 patients from 6 European countries other than Italy (European patients) were enrolled in the registry, and followed up until December 2014. Italian patients were the oldest (mean age 65.7 years) among the European patients. The Italian patients with a history of cancer were 24.6 % of whom 63.2 % had an active cancer (18.2 and 57.0 %, respectively, in Europe). Parenteral heparin was given, as initial treatment, in 73.8 % of Italian patients (66.4 % in Europe); VKA in combination with other treatments in 45.8 % (34.7 % in Europe); and VKA as the only anticoagulant treatment in 24.4 % (17.2 % in Europe). Of the Italian patients, 43.2 and 90.6 % of patients were hospitalized for deep vein thrombosis and pulmonary embolism, respectively; 65.4 % were admitted to the hospital through the emergency department. Following a real world approach, PREFER in VTE shows that the Italian patients, among and compared to the European patients, are the oldest, have a history of cancer more commonly, receive an initial treatment with heparin more commonly, and are more commonly hospitalized, particularly if affected by PE